biote Corp. (BTMD) grants options and RSUs to director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
biote Corp. director Stephen Mark Cone received new equity awards in the form of options and deferred settlement RSUs. He was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, vesting in full on the earlier of May 12, 2027 or the day prior to the 2027 annual meeting, subject to continued service.
He also received 31,481 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, but settlement is deferred until his separation from service. Following these awards, he holds 130,000 options and 69,822 Deferred Settlement RSUs directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Cone Stephen Mark
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Settlement RSU | 31,481 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 130,000 | $0.00 | -- |
Holdings After Transaction:
Deferred Settlement RSU — 69,822 shares (Direct, null);
Stock Option (Right to Buy) — 130,000 shares (Direct, null)
Footnotes (1)
- Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the date of the Reporting Person's separation from service. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Stock options granted: 130,000 options
Deferred Settlement RSUs granted: 31,481 RSUs
Options held after grant: 130,000 options
+2 more
5 metrics
Stock options granted
130,000 options
Exercise price <money>$2.20</money> per share; vesting by May 2027
Deferred Settlement RSUs granted
31,481 RSUs
Fully vested upon grant; settlement at separation from service
Options held after grant
130,000 options
Total options following the reported award
Deferred Settlement RSUs held after grant
69,822 RSUs
Total RSUs following the reported award
Option expiration date
<date>May 11, 2036</date>
Expiration of newly granted stock options
Key Terms
Deferred Settlement RSU, economic equivalent, separation from service, vest
4 terms
Deferred Settlement RSU financial
"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."
economic equivalent financial
"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."
separation from service financial
"settlement will be deferred until the date of the Reporting Person's separation from service."
vest financial
"All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider equity awards did biote (BTMD) disclose for Stephen Mark Cone?
biote disclosed that director Stephen Mark Cone received 130,000 stock options and 31,481 Deferred Settlement RSUs. Both awards relate to Class A Common Stock and were reported as compensation grants rather than open-market purchases or sales.
What is the exercise price and vesting schedule of Cone's new biote (BTMD) stock options?
Cone’s new options cover 130,000 shares at an exercise price of $2.20 per share. All option shares vest on the earlier of May 12, 2027 or the day before the 2027 annual stockholders meeting, assuming his continuous service.
How do the Deferred Settlement RSUs granted to Cone at biote (BTMD) work?
Each Deferred Settlement RSU equals one share of Class A Common Stock. These RSUs are fully vested when granted, but the actual share settlement is deferred until Stephen Mark Cone’s separation from service with the company.
How many Deferred Settlement RSUs does Stephen Mark Cone hold after this biote (BTMD) Form 4?
After this filing, Cone holds 69,822 Deferred Settlement RSUs directly. The latest grant added 31,481 RSUs, and each unit is economically equivalent to one share of the company’s Class A Common Stock.
Are Stephen Mark Cone’s biote (BTMD) Form 4 transactions open-market buys or sells?
The reported transactions are equity compensation grants, not open-market trades. Both the stock options and Deferred Settlement RSUs were recorded with code A as grant, award, or other acquisition rather than purchases or sales in the market.